How Global Research Models Point the Way Forward for U.S. Hospitals
As U.S. hospitals rethink their dependence on traditional medical tourism, one proven model for sustainable international engagement already exists—multi-country clinical trials. These large-scale, collaborative studies demonstrate how institutions can participate in global health markets without relying solely on patient travel.
Clinical Trials as a Multi-Modal Blueprint
Modern clinical trials are inherently multi-modal. They involve:
- Cross-border digital exchange (Mode 1): Sharing data, results, and protocols across research sites using digital platforms and AI-assisted analytics.
- International participant recruitment (Mode 2): Engaging patients across countries for inclusion in studies.
- Foreign investment and partnerships (Mode 3): Establishing or partnering with trial sites abroad, often co-branded with U.S. institutions.
- Movement of professionals and knowledge (Mode 4): Deploying researchers, clinicians, and data specialists across borders to ensure quality and compliance.
This approach mirrors what a reimagined global health strategy could look like—diversified, collaborative, and less dependent on physical travel.
The Market Opportunity
The global clinical trials market was valued at approximately $50 billion in 2023 and is projected to reach $85 billion by 2032. That scale of opportunity equals—or even exceeds—the total medical tourism market. In other words, research collaboration offers not just academic prestige, but commercial and strategic advantages for health systems seeking international presence.
U.S. Leadership in Global Trials
U.S. academic medical centers have already demonstrated leadership, particularly in oncology, neurology, and infectious disease trials. These institutions often serve as coordinating hubs for multi-country research networks, leveraging their expertise in trial design, regulatory standards, and patient care.
By participating in such efforts, hospitals achieve benefits that extend far beyond research outcomes:
- Faster patient recruitment through global access.
- Improved diversity in study populations, leading to more inclusive science.
- Knowledge exchange between U.S. and foreign clinicians.
- Enhanced institutional reputation as an international collaborator.
Each of these advantages strengthens the foundation for sustainable global engagement—benefiting international patient service departments, research divisions, and overall brand recognition.
Beyond Tourism: Toward Knowledge-Driven Collaboration
The success of multi-country trials underscores a fundamental truth: the future of global health trade lies in knowledge, collaboration, and data, not just the movement of patients. U.S. hospitals that align their international strategies with these principles will be better positioned to thrive in a borderless healthcare economy—one defined by partnerships rather than passports.
💡 Be sure to join moderator, Irving Stackpole, for “Reframing the Global HealthScape for US Hospitals: Next-Gen Competitive Models” at the 2025 USCIPP Annual Meeting,
🗓 December 5, 2025 | 10:45–11:30 AM ET,
with Elizabeth Ziemba, Founder and President, Medical Tourism Training, Inc., and Deepak Asudani, MD, International Medical Director, UC San Diego Health.
👉 Learn more: https://stackpoleassociates.com/2025-uscipp/